<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39231788</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1976-555X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of veterinary science</Title><ISOAbbreviation>J Vet Sci</ISOAbbreviation></Journal><ArticleTitle>Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.</ArticleTitle><Pagination><StartPage>e63</StartPage><MedlinePgn>e63</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e63</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4142/jvs.23325</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Glutamic acid decarboxylase 67 (GAD67) is a gamma-aminobutyric acid (GABA) synthesis enzyme associated with the function of other neurotransmitter receptors, such as the N-methyl-D-aspartate (NMDA) receptor and cannabinoid receptor 1. However, the role of GAD67 in the development of different abused drug-induced reward behaviors remains unknown. In order to elucidate the mechanisms of substance use disorder, it is crucial to study changes in biomarkers within the brain's reward circuit induced by drug use.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study was designed to examine the effects of the downregulation of GAD67 expression in the dorsal striatum on reward behavior development.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the effects of GAD67 knockdown on depression-like behavior and anxiety using the forced swim test and elevated plus maze test in a mouse model. We further determined the effects of GAD67 knockdown on ketamine- and JWH-018-induced conditioned place preference (CPP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Knockdown of GAD67 in the dorsal striatum of mice increased depression-like behavior, but it decreased anxiety. Moreover, the CPP score on the NMDA receptor antagonist ketamine was increased by GAD67 knockdown, whereas the administration of JWH-018, a cannabinoid receptor agonist, did not affect the CPP score in the GAD67 knockdown mice group compared with the control group.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">These results suggest that striatal GAD67 reduces GABAergic neuronal activity and may cause ketamine-induced NMDA receptor inhibition. Consequently, GAD67 downregulation induces vulnerability to the drug reward behavior of ketamine.</AbstractText><CopyrightInformation>© 2024 The Korean Society of Veterinary Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gu</LastName><ForeName>Sun Mi</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-7907-0487</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hong</LastName><ForeName>Eunchong</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0007-4882-6492</Identifier><AffiliationInfo><Affiliation>Non-Clinical Center, Osong Medical Innovation Foundation, Cheongju 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sowoon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0006-8239-9570</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sanghyeon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-8823-3035</Identifier><AffiliationInfo><Affiliation>Stanley Brain Research Laboratory, Stanley Medical Research Institute, Rockville, MD 20850, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seong Shoon</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-8182-1024</Identifier><AffiliationInfo><Affiliation>College of Korean Medicine, Daegu Haany University, Daegu 42158, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0009-0002-9523-0759</Identifier><AffiliationInfo><Affiliation>College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea. chahj@gnu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Jaesuk</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3093-8919</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea. jyun@chungbuk.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20182MFDS425</GrantID><Acronym>MFDS</Acronym><Agency>Ministry of Food and Drug Safety</Agency><Country>Korea</Country></Grant><Grant><GrantID>22214MFDS252</GrantID><Acronym>MFDS</Acronym><Agency>Ministry of Food and Drug Safety</Agency><Country>Korea</Country></Grant><Grant><GrantID>23212MFDS217</GrantID><Acronym>MFDS</Acronym><Agency>Ministry of Food and Drug Safety</Agency><Country>Korea</Country></Grant><Grant><GrantID>2017R1A5A2015541</GrantID><Acronym>NRF</Acronym><Agency>National Research Foundation of Korea</Agency><Country>Korea</Country></Grant><Grant><GrantID>2021RIS-001</GrantID><Acronym>NRF</Acronym><Agency>National Research Foundation of Korea</Agency><Country>Korea</Country></Grant><Grant><GrantID>NRF-2021R1I1A1A01058188</GrantID><Acronym>NRF</Acronym><Agency>National Research Foundation of Korea</Agency><Country>Korea</Country></Grant><Grant><Acronym>GNU</Acronym><Agency>Gyeongsang National University</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Vet Sci</MedlineTA><NlmUniqueID>100964185</NlmUniqueID><ISSNLinking>1229-845X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="D005968">Glutamate Decarboxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.15</RegistryNumber><NameOfSubstance UI="C402565">glutamate decarboxylase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005968" MajorTopicYN="Y">Glutamate Decarboxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009281" MajorTopicYN="N">Naphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GAD67</Keyword><Keyword MajorTopicYN="N">JWH-018</Keyword><Keyword MajorTopicYN="N">conditioned place preference</Keyword><Keyword MajorTopicYN="N">gamma-aminobutyric acid</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39231788</ArticleId><ArticleId IdType="pmc">PMC11450393</ArticleId><ArticleId IdType="doi">10.4142/jvs.23325</ArticleId><ArticleId IdType="pii">25.e63</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper S, Robison AJ, Mazei-Robison MS. Reward circuitry in addiction. Neurotherapeutics. 2017;14(3):687–697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509624</ArticleId><ArticleId IdType="pubmed">28324454</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman MA, Roberto M. The addicted brain: understanding the neurophysiological mechanisms of addictive disorders. Front Integr Nuerosci. 2015;9:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365688</ArticleId><ArticleId IdType="pubmed">25852502</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashchinkina E, Panhelainen A, Aitta-Aho T, Korpi ER. GABAA receptor drugs and neuronal plasticity in reward and aversion: focus on the ventral tegmental area. Front Pharmacol. 2014;5:256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243505</ArticleId><ArticleId IdType="pubmed">25505414</ArticleId></ArticleIdList></Reference><Reference><Citation>Nudmamud-Thanoi S, Veerasakul S, Thanoi S. Pharmacogenetics of drug dependence: Polymorphisms of genes involved in GABA neurotransmission. Neurosci Lett. 2020;726:134463.</Citation><ArticleIdList><ArticleId IdType="pubmed">31472163</ArticleId></ArticleIdList></Reference><Reference><Citation>Freese L, Muller EJ, Souza MF, Couto-Pereira NS, Tosca CF, Ferigolo M, et al. GABA system changes in methylphenidate sensitized female rats. Behav Brain Res. 2012;231(1):181–186.</Citation><ArticleIdList><ArticleId IdType="pubmed">22460063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Zhu YS, Li SB. Polymorphisms in the glutamate decarboxylase 1 gene associated with heroin dependence. Biochem Biophys Res Commun. 2012;422(1):91–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22564729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ade KK, Janssen MJ, Ortinski PI, Vicini S. Differential tonic GABA conductances in striatal medium spiny neurons. J Neurosci. 2008;28(5):1185–1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671393</ArticleId><ArticleId IdType="pubmed">18234896</ArticleId></ArticleIdList></Reference><Reference><Citation>Heusner CL, Beutler LR, Houser CR, Palmiter RD. Deletion of GAD67 in dopamine receptor-1 expressing cells causes specific motor deficits. Genesis. 2008;46(7):357–367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360952</ArticleId><ArticleId IdType="pubmed">18615733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA, Horváth S, Garbett KA, Schmidt MJ, Everheart M, Gellért L, et al. The role of cannabinoid 1 receptor expressing interneurons in behavior. Neurobiol Dis. 2014;63:210–221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946968</ArticleId><ArticleId IdType="pubmed">24239560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossato A, Uccelli L, Bilel S, Canazza I, Di Domenico G, Pasquali M, et al. Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48: behavioral, neurochemical, and dopamine transporter scan imaging studies in mice. Front Psychiatry. 2017;8:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543288</ArticleId><ArticleId IdType="pubmed">28824464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Xia J, Han Q, Liu D, Xiong W. The synthetic cannabinoid dehydroxylcannabidiol restores the function of a major GABAA receptor isoform in a cell model of hyperekplexia. J Biol Chem. 2020;295(1):138–145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952599</ArticleId><ArticleId IdType="pubmed">31757808</ArticleId></ArticleIdList></Reference><Reference><Citation>Celotto L, Eroli F, Nistri A, Vilotti S. Long-term application of cannabinoids leads to dissociation between changes in cAMP and modulation of GABAA receptors of mouse trigeminal sensory neurons. Neurochem Int. 2019;126:74–85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30633953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu SM, Seo S, Park D, Kim S, Lamichhane S, Han KM, et al. Cannabinoid receptor type 1 regulates drug reward behavior via glutamate decarboxylase 67 transcription. Int J Mol Sci. 2021;22(19):10486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8508987</ArticleId><ArticleId IdType="pubmed">34638827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol. 2014;25(8):750–757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216610</ArticleId><ArticleId IdType="pubmed">25325289</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Lin D, Wu B, Zhou W. Ketamine abuse potential and use disorder. Brain Res Bull. 2016;126(Pt 1):68–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">27261367</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WK, Liang HJ, Lau CG, Tang A, Ungvari GS. Relationship between cognitive impairment and depressive symptoms in current ketamine users. J Stud Alcohol Drugs. 2013;74(3):460–468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23490576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung EY, Cha HJ, Min HK, Yun J. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res. 2021;44(4):402–413.</Citation><ArticleIdList><ArticleId IdType="pubmed">33811300</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujihara K, Miwa H, Kakizaki T, Kaneko R, Mikuni M, Tanahira C, et al. Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes. Neuropsychopharmacology. 2015;40(10):2475–2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538341</ArticleId><ArticleId IdType="pubmed">25904362</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberbauer LR, Spurny B, Handschuh P, Klöbl M, Bednarik P, Reiter B, et al. Effect of ketamine on limbic GABA and glutamate: a human in vivo multivoxel magnetic resonance spectroscopy study. Front Psychiatry. 2020;11:549903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507577</ArticleId><ArticleId IdType="pubmed">33101078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019;199:58–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">30851296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Jo Y, Webster MJ, Lee D. Shared co-expression networks in frontal cortex of the normal aged brain and schizophrenia. Schizophr Res. 2019;204:253–261.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Webster MJ. The Stanley Neuropathology Consortium Integrative Database (SNCID) for psychiatric disorders. Neurosci Bull. 2019;35(2):277–282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426894</ArticleId><ArticleId IdType="pubmed">30484114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzschentke TM. In: Encyclopedia of Psychopharmacology. Stolerman IP, Price LH, editors. Springer; 2010. Conditioned place preference and aversion; pp. 1–7.</Citation></Reference><Reference><Citation>Chu J, Deyama S, Li X, Motono M, Otoda A, Saito A, et al. Role of 5-HT1A receptor-mediated serotonergic transmission in the medial prefrontal cortex in acute restraint stress-induced augmentation of rewarding memory of cocaine in mice. Neurosci Lett. 2021;743:135555.</Citation><ArticleIdList><ArticleId IdType="pubmed">33352288</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz M, Khayat A, Yaka R. GABAergic projections to the ventral tegmental area govern cocaine-conditioned reward. Addict Biol. 2021;26(4):e13026.</Citation><ArticleIdList><ArticleId IdType="pubmed">33638301</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong MX, Chen GH, Hu L. Dopaminergic system alteration in anxiety and compulsive disorders: a systematic review of neuroimaging studies. Front Neurosci. 2020;14:608520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744599</ArticleId><ArticleId IdType="pubmed">33343291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Chammas C, Soghomonian JJ. Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Neuroscience. 2015;303:586–594.</Citation><ArticleIdList><ArticleId IdType="pubmed">26188284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019;179:55–62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581196</ArticleId><ArticleId IdType="pubmed">30768942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Witten IB. Striatal circuits for reward learning and decision-making. Nat Rev Neurosci. 2019;20(8):482–494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231228</ArticleId><ArticleId IdType="pubmed">31171839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, Kalsi G, Prescott CA, Hodgkinson CA, Goldman D, Alexander J, et al. Associations of glutamate decarboxylase genes with initial sensitivity and age-at-onset of alcohol dependence in the Irish Affected Sib Pair Study of Alcohol Dependence. Drug Alcohol Depend. 2009;101(1-2):80–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844896</ArticleId><ArticleId IdType="pubmed">19111404</ArticleId></ArticleIdList></Reference><Reference><Citation>Levran O, Peles E, Randesi M, Correa da Rosa J, Ott J, Rotrosen J, et al. Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:118–123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4564302</ArticleId><ArticleId IdType="pubmed">26277529</ArticleId></ArticleIdList></Reference><Reference><Citation>Botanas CJ, de la Peña JB, Dela Peña IJ, Tampus R, Yoon R, Kim HJ, et al. Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: evidence of its abuse potential. Pharmacol Biochem Behav. 2015;133:31–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">25792291</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus MM, Mathé JM, Nomikos GG, Svensson TH. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology. 2001;40(4):482–490.</Citation><ArticleIdList><ArticleId IdType="pubmed">11249957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic N, Kühne C, Jakovcevski M, Hartmann J, Genewsky AJ, Gomes KS, et al. Chronic CRH depletion from GABAergic, long-range projection neurons in the extended amygdala reduces dopamine release and increases anxiety. Nat Neurosci. 2018;21(6):803–807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6951443</ArticleId><ArticleId IdType="pubmed">29786085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci. 2006;26(5):1604–1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675509</ArticleId><ArticleId IdType="pubmed">16452684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KB, Andersen HK. Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling. Int J Mol Sci. 2020;21(17):6115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503917</ArticleId><ArticleId IdType="pubmed">32854313</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper JM, Koós T, Ibanez-Sandoval O, Tecuapetla F, Faust TW, Assous M. Heterogeneity and diversity of striatal GABAergic interneurons: update 2018. Front Neuroanat. 2018;12:91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6235948</ArticleId><ArticleId IdType="pubmed">30467465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369–377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123717</ArticleId><ArticleId IdType="pubmed">27853201</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160(3):585–593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931559</ArticleId><ArticleId IdType="pubmed">20100276</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggan SM, Lazarus MS, Stoyak SR, Volk DW, Glausier JR, Huang ZJ, et al. Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biol Psychiatry. 2012;71(2):114–119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237751</ArticleId><ArticleId IdType="pubmed">22036037</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>